Results 111 to 120 of about 50,593 (147)
Some of the next articles are maybe not open access.
A small-molecule inhibitor of skeletal muscle myosin II
Nature Cell Biology, 2001We screened a small-molecule library for inhibitors of rabbit muscle myosin II subfragment 1 (S1) actin-stimulated ATPase activity. The best inhibitor, N-benzyl-p-toluene sulphonamide (BTS), an aryl sulphonamide, inhibited the Ca2+-stimulated S1 ATPase, and reversibly blocked gliding motility.
A, Cheung +6 more
openaire +2 more sources
2,3-Butanedione monoxime (BDM) as a myosin inhibitor
Journal of Muscle Research & Cell Motility, 20022,3-Butanedione monoxime (BDM) is the well-characterized, low-affinity, non-competitive inhibitor of skeletal muscle myosin-II. It has been widely used at millimolar concentrations in cell biological experiments with the assumption that it is an ATPase inhibitor of the myosin superfamily. To determine the usefulness of BDM as a general myosin inhibitor,
openaire +2 more sources
The development of novel myosin inhibitors
2011This thesis describes a structure activity relationship (SAR) study on the recently discovered small molecule tool blebbistatin (S)-21 with particular emphasis on the development of novel synthetic protocols suitable for the rapid synthesis of libraries of blebbistatin analogues.
openaire +2 more sources
Advances in Cardiovascular Pharmacotherapy. I. Cardiac Myosin Inhibitors
Journal of Cardiothoracic and Vascular AnesthesiaHypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy. The disease is characterized by asymmetric left ventricular (LV) remodeling with myocyte disarray and interstitial fibrosis, a hypercontractile state, dynamic subaortic obstruction of the LV outflow tract, impaired LV diastolic function, atrial and ventricular arrhythmias ...
Paul S, Pagel +3 more
openaire +2 more sources
The Revolution of Cardiac Myosin Inhibitors in Patients With Hypertrophic Cardiomyopathy
Canadian Journal of CardiologyHypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy worldwide and causes significant morbidity and mortality. For decades, medical treatment options have been limited and untargeted, with frequent need for invasive interventions not readily accessible to many HCM patients.
Rebecca Haraf, Hany Habib, Ahmad Masri
openaire +2 more sources
Two cardiac myosin inhibitors in the treatment of obstructive hypertrophic cardiomyopathy
MedA key area of therapeutic progress in obstructive hypertrophic cardiomyopathy revolves around the emergence of cardiac myosin inhibitors, of which mavacamten and aficamten represent the first and second molecules. We summarize the key research evidence, including many similarities and potential differences between various clinical trials studying these
Milind Y, Desai, Eugene, Braunwald
openaire +2 more sources
Myosin inhibitor flexes, myosin activator flops
Nature Reviews Drug Discovery, 2020openaire +1 more source
A New Chapter in the Management of Hypertrophic Cardiomyopathy: Cardiac Myosin Inhibitors
Cardiologia Hungarica, 2023Eszter Dalma Palinkaš, Robert Sepp
exaly
Myosin Inhibitors: The Next Generation.
Journal of the American College of Cardiology, 2023Ajith, Nair +2 more
openaire +1 more source